[Skip to Content]
[Skip to Content Landing]
Article
September 1963

A Double-Blind Study of IDU in Human Herpes Simplex Keratitis

Author Affiliations

Portland, Ore
From the John E. Weeks Institute for the Advancement of Ophthalmology, University of Oregon Medical School.

Arch Ophthalmol. 1963;70(3):381-384. doi:10.1001/archopht.1963.00960050383020
Abstract

Since the introduction of 5-iodo-2'-deoxyuridine (IDU) by Kaufman1 as a treatment for herpes simplex keratitis, there has been a great arousal of interest in antiviral chemotherapy. Effectiveness of this drug was first demonstrated in controlled studies of the eyes of rabbits2,3 and has been confirmed in a controlled laboratory study at another institution.4

Following the initial reports of the controlled laboratory studies, there have been a number of clinical reports describing a universally beneficial effect of this drug in human herpetic disease, in series ranging in size from two to five hundred patients.5-12 All of these reports have been uncontrolled and thereby have overlooked two basic facts about human herpes simplex keratitis, that it is a self-limited disease, and that, with the exception of the rarely recognized primary infection, it is a recurrent infection which develops in the presence of adequate antibody level, not the same

First Page Preview View Large
First page PDF preview
First page PDF preview
×